1. AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three virtual investor conferences in September 2021.  

    Presentation Details

    Conference: Citi 16th Annual BioPharma Virtual Conference
    Format: Panel Discussion, "Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics"
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Date: September 9, 2021
    Time: 1:25 p.m. EST

    Conference: H.C. Wainwright…

    AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three virtual investor conferences in September 2021.  

    Presentation Details

    Conference: Citi 16th Annual BioPharma Virtual Conference

    Format: Panel Discussion, "Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics"

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: September 9, 2021

    Time: 1:25 p.m. EST

    Conference: H.C. Wainwright 23rd Annual Global Investment Conference

    Format: Corporate Presentation

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: September 13, 2021

    Time: 7:00 a.m. EST

    Conference: Morgan Stanley 19th Annual Global Healthcare Conference

    Format: Fireside Chat

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, M.B.A., Shattuck's Chief Financial Officer

    Date: September 15, 2021

    Time: 11:45 a.m. EST

    A live webcast of the panel discussion, corporate presentation, and fireside chat will be available on the Events & Presentations section of the Company's website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com

     



    Primary Logo

    View Full Article Hide Full Article
  2. – Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 –

    – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies –

    – Announced plans to study SL-172154 in hematologic malignancies, Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS), with an IND filing anticipated in the fourth quarter of 2021 –

    – Reported plans to continue dose escalating in the SL-279252 (PD1-Fc-OX40L)

    – Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 –

    – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies –

    – Announced plans to study SL-172154 in hematologic malignancies, Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS), with an IND filing anticipated in the fourth quarter of 2021 –

    – Reported plans to continue dose escalating in the SL-279252 (PD1-Fc-OX40L) Phase 1 trial in advanced solid tumors based on trends in immune response data –

    AUSTIN, TX and DURHAM, NC, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.

    "Over the past quarter we have begun to compare and contrast the immunological effects of CD40 and OX40 stimulation in cancer patients treated with SL-172154 and SL-279252. We believe the emerging data validate the hypothesis that the ARC platform can uniquely activate the TNF superfamily and indicate that the effects of OX40 stimulation are far more subtle than innate immune stimulation of CD40. We are excited to share this data in just a few months' time at the SITC Annual Meeting," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "Discharging the perceived safety risks associated with dose-escalating a CD40 agonist has enabled us to broaden our clinical development strategy, including an expected IND application for expansion into both Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome in the fourth quarter of this year."

    Second Quarter 2021 Recent Business Highlights and Other Recent Developments

    ARC Clinical-Stage Pipeline

    • Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Ovarian Cancer with Encouraging Safety Profile: The phase 1 trial is an open label, multi-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered intravenously in patients with platinum resistant ovarian cancer. SL-172154 is a dual CD47/SIRPα inhibitor and CD40 agonist. Today, Shattuck reported continued enrollment at the fourth dose level, 3.0 mg/kg, and plans to advance to the next dose level, 10.0 mg/kg. To date, no evidence of anemia, thrombocytopenia, cytokine release syndrome or liver dysfunction, nor other dose-limiting toxicities have been observed. Prior CD40 agonist antibodies have encountered dose limiting toxicities at doses of greater than 0.3 mg/kg. Initial dose-escalation data from the trial have been submitted for presentation at the SITC Annual Meeting, to be held in November 2021.
    • Anticipated IND Application for SL-172154 in AML and HR-MDS: Shattuck plans to submit to the U.S. Food and Drug Administration an investigational new drug application for a phase 1A/B clinical trial for SL-172154 in patients with AML and HR-MDS, anticipated in the fourth quarter of 2021. The trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154, as both monotherapy and in combination. In AML, Shattuck plans to evaluate SL-172154 in combination with both azacitidine and venetoclax. In both HR-MDS and TP53 mutant AML, Shattuck plans to evaluate SL-172154 in combination with azacitidine.
    • Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Squamous Cell Carcinoma of the Head and Neck or Skin: Shattuck continues to enroll patients in a Phase 1 clinical trial for SL-172154, administered intratumorally, in patients with squamous cell carcinoma of the head and neck or skin. The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 as monotherapy. Initial dose-escalation data from the trial are expected in the first half of 2022.
    • Additional Dose Escalation Cohorts Added to the SL-279252 Phase 1 Clinical Trial: An analysis of data collected across a dose range of 0.0001 through 6.0 mg/kg, on two dosing schedules, demonstrated dose dependent OX40 receptor engagement of OX40 expressing T cells, and a primary pharmacodynamic effect showing rapid egress of these target cells from circulation. This effect has not been reported for prior OX40 agonist antibodies. No dose-limiting toxicities have been observed to date. Based on these data Shattuck plans to enroll additional patients at dose levels of 12.0 and 24.0 mg/kg. Because very few of the patients treated to date are known to express PD-L1 within the tumor, Shattuck plans to enroll patients with known PD-L1 positive tumors in the additional dose level cohorts. The Phase 1 trial is an open label, multi-center, dose escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-279252 as monotherapy in patients with advanced solid tumors. SL-279252 is currently being developed in collaboration with Takeda Pharmaceuticals. An abstract containing data from the dose-escalation cohorts through 6.0 mg/kg has been submitted to the SITC Annual Meeting, to be held in November 2021.

    Corporate

    • Appointed Chief Technical Officer: In June 2021, Abhinav A. Shukla was appointed Chief Technical Officer. Prior to joining Shattuck, Dr. Shukla was the Chief Technical Operations Officer at Redpin Therapeutics and was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing. Previously he held several senior leadership positions, including Vice President of Manufacturing at CRISPR Therapeutics, Vice President and Head of Biologics Process Development at Shire, and Senior Vice President of Process Development and Manufacturing at KBI Biopharma. Shukla received his doctorate in Chemical and Biochemical Engineering from Rensselaer Polytechnic Institute and his undergraduate degree from the Indian Institute of Technology, Delhi.

    Second Quarter 2021 Financial Results

    • Cash Position: As of June 30, 2021, cash and cash equivalents and short-term investments were $304.8 million, as compared to $335.4 million as of December 31, 2020.
    • Collaboration Revenue: Revenue for the second quarter ended June 30, 2021 was $(4.2) million, as compared to $3.2 million for the second quarter ended June 30, 2020. The negative revenue was driven by increased expected costs required to complete the performance obligation contained in the Collaboration Agreement with Takeda as a result of changes to the SL-279252 clinical development plan.
    • Research and Development (R&D) Expenses: R&D expenses for the second quarter ended June 30, 2021 were $14.9 million, as compared to $7.8 million for the second quarter ended June 30, 2020. The increase was primarily driven by increases in clinical development, manufacturing, personnel-related costs, and laboratory capabilities.
    • General and Administrative (G&A) Expenses: G&A expenses for the second quarter ended June 30, 2021, were $5.4 million, as compared to $1.7 million for the second quarter ended June 30, 2020. The increase was primarily driven by an increase in personnel related costs to support the operational expansion and costs associated with being a public company.
    • Net Loss: Net loss was $23.6 million for the second quarter ended June 30, 2021, or $0.56 per basic and diluted share, as compared to a net loss of $6.2 million for the second quarter ended June 30, 2020, or $0.81 per basic and diluted share.

    2021 Financial Guidance

    Shattuck believes its cash and cash equivalents and short-term investments will be sufficient to fund its operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the Company's current operational plans and excludes any additional funding that may be received or business development or additional clinical development activities that may be undertaken.

    About SL-172154

    SL-172154 is an investigational bi-functional fusion protein designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway. SL-172154 is currently being evaluated in Phase 1 clinical trials for the treatment of patients with ovarian and head and neck or skin squamous cell carcinoma.

    In preclinical studies, SL-172154, demonstrated evidence of bridging the innate and adaptive immunity, antigen cross-priming to CD8+ T cells, and durable receptor occupancy, leading to superior anti-tumor activity over anti-CD47 antibodies, and anti-CD40 antibodies, both alone or in combination. Additionally, SL-172154 preclinically demonstrated a favorable safety profile with no evidence of hematologic toxicities observed with other CD47 inhibitors.

    About SL-279252

    SL-279252 is an investigational bi-functional fusion protein designed to block the PD-1 immune checkpoint and simultaneously agonize the OX40 pathway. SL-279252 is currently being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors and lymphoma. SL-279252 is part of a collaboration with Takeda Pharmaceuticals.

    In preclinical studies, SL-279252, demonstrated evidence of high monotherapy activity, potent stimulation of OX40+ T Cells and superior anti-tumor activity over Anti-PD1/L-1 antibodies and Anti-OX40 antibodies, both alone or in combination.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our preclinical studies, clinical trials and research and development programs, the initiation of any dose-expansion cohorts, the anticipated timing of the results from those studies and trials, the anticipated timing for IND filings, anticipated timing for preclinical development updates, the potential for our proprietary ARC technology and GADLEN platform, the clinical benefit of TIGIT blocking antibodies and T cell engagers, additional uses for our proprietary ARC technology and GADLEN platform, potential new uses for our product candidates, and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated public health guidance measures; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent periodic and current reports filed with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com

    SHATTUCK LABS, INC.

    BALANCE SHEETS 

    (In thousands)

     June 30, 2021December 31, 

    2020
     (unaudited)
    Assets  
    Current assets:  
    Cash and cash equivalents$86,494  $157,898  
    Short-term investments218,304  177,551  
    Prepaid expenses and other current assets11,080  10,190  
    Total current assets315,878  345,639  
    Property and equipment, net7,571  3,000  
    Other assets331  349  
    Total assets$323,780  $348,988  
       
    Liabilities and Stockholders' Equity  
    Current liabilities:  
    Accounts payable$1,007  $1,754  
    Accrued expenses11,326  7,352  
    Deferred revenue2,778  7,728  
    Total current liabilities15,111  16,834  
    Deferred revenue, net of current portion29,215  21,306  
    Deferred rent2,367  987  
    Total liabilities46,693  39,127  
    Stockholders' equity:  
    Common stock5  5  
    Additional paid-in capital386,206  382,012  
    Accumulated other comprehensive loss(1,620) (63) 
    Accumulated deficit(107,504) (72,093) 
    Total stockholders' equity277,087  309,861  
    Total liabilities and stockholders' equity$323,780  $348,988  

    SHATTUCK LABS, INC.

    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited) 

    (In thousands, except share and per share amounts)

     Three Months Ended June 30, Six Months Ended June 30,
     2021

      2020 2021 2020
    Collaboration revenue - related party$(4,231)  $3,181   $(1,961)  $6,157  
    Operating expenses:                   
    Research and development 14,882   7,755   25,219   15,892  
    General and administrative 5,399   1,746   9,755   3,346  
    Expense from operations 20,281   9,501   34,974   19,238  
    Loss from operations (24,512)  (6,320)  (36,935)  (13,081) 
                        
    Other income (expense):                   
    Interest income 1,000   138   1,696   387  
    Other (86)  (26)  (172)  (68) 
    Total other income 914   112   1,524   319  
    Net loss$(23,598)  $(6,208)  $(35,411)  $(12,762) 
    Unrealized loss on short-term investments (960)  (97)  (1,557)  (36) 
    Comprehensive loss$(24,558)  $(6,305)  $(36,968)  $(12,798) 
            
    Net loss per share – basic and diluted$(0.56)  $(0.81)  $(0.85)  $(1.67) 
    Weighted-average shares outstanding – basic and diluted 41,906,268   7,646,149   41,840,555   7,633,565  



    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

    Presentation Details
    Conference: BTIG Biotechnology Conference
    Format: Fireside Chat
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, Lini Pandite, MBChB, M.B.A, Shattuck's Chief Medical Officer, and Andrew Neill, M.B.A, Shattuck's Chief Financial Officer
    Date: August 10, 2021
    Time: 1:30 p.m. EST

    The…

    AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

    Presentation Details

    Conference: BTIG Biotechnology Conference

    Format: Fireside Chat

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, Lini Pandite, MBChB, M.B.A, Shattuck's Chief Medical Officer, and Andrew Neill, M.B.A, Shattuck's Chief Financial Officer

    Date: August 10, 2021

    Time: 1:30 p.m. EST

    The live webcast will be available on BTIG's conference website at the time of the event, and a replay will be available through BTIG's research access.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com 



    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

    The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288. The live and archived webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast…

    AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

    The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288. The live and archived webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer.

    "We are extremely pleased to have Abhinav on our executive team. His demonstrated leadership across the full spectrum of biologics manufacturing, and more recently in gene therapy, will be critical as we continue to build our internal capabilities to support ARC and GADLEN platform compounds through clinical development," said Taylor Schreiber, M.D…

    AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer.

    "We are extremely pleased to have Abhinav on our executive team. His demonstrated leadership across the full spectrum of biologics manufacturing, and more recently in gene therapy, will be critical as we continue to build our internal capabilities to support ARC and GADLEN platform compounds through clinical development," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.

    "This is an incredibly exciting time to join Shattuck," said Dr. Shukla, Ph.D. "With two clinical-stage ARC compounds and two novel protein engineering platforms, Shattuck is uniquely positioned to expand the therapeutic application of bi-functional fusion proteins. I am particularly excited to work with the executive team to further the development of both ARC and GADLEN compounds."

    Dr. Shukla joins Shattuck from Redpin Therapeutics, where he was the Chief Technical Operations Officer and was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing. Previously, he held several senior leadership positions, including Vice President of Manufacturing at CRISPR Therapeutics, Vice President and Head of Biologics Process Development at Shire, Senior Vice President of Process Development and Manufacturing at KBI Biopharma, and in senior scientific roles at Bristol-Myers Squibb and Amgen prior to KBI. Throughout his career, Dr. Shukla has been involved in over 75 investigational new drug applications as well as the commercialization of several therapeutics, including Yervoy®, Orencia®, and Nulojix®. Dr. Shukla received his doctorate in Chemical and Biochemical Engineering from Rensselaer Polytechnic Institute and his undergraduate degree from the Indian Institute of Technology, Delhi.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  6. – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –

    – IND filings for SL-172154 in hematologic malignancies anticipated in the second half of 2021 –

    – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 –

    AUSTIN, TX and DURHAM, NC, May 10, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported…

    – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –

    – IND filings for SL-172154 in hematologic malignancies anticipated in the second half of 2021 –

    – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 –

    AUSTIN, TX and DURHAM, NC, May 10, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the first quarter ended March 31, 2021 and provided recent business highlights.

    "We have made steady progress across the organization this quarter and remain on-track to present clinical data from both SL-172154 and SL-279252 in the second half of this year," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "In addition, we accelerated our expansion of SL-172154 into hematologic malignancies, and we plan to announce our strategy to bridge an immunologically active dose identified in our ovarian cancer study into multiple hematologic indications in the second half of 2021."

    First Quarter 2021 Recent Business Highlights and Other Recent Developments

    • Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Ovarian Cancer: Shattuck continues to enroll patients in a Phase 1 clinical trial for its lead wholly owned asset SL-172154, a dual CD47/SIRPα inhibitor and CD40 agonist. The Phase 1 trial is an open label, multi-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered intravenously in patients with ovarian cancer. Initial dose-escalation data from the trial are expected in the second half of 2021.
    • Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Squamous Cell Carcinoma of the Head and Neck or Skin: Shattuck continues to enroll patients in a Phase 1 clinical trial for SL-172154, administered intratumorally. The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 in patients with squamous cell carcinoma of the head and neck or skin. Initial dose-escalation data from the trial are expected in the first half of 2022.
    • Continued Enrollment of SL-279252 Phase 1 Clinical Trial: Shattuck continues to enroll patients in a Phase 1 clinical trial evaluating SL-279252, a dual PD-1/PD-L1 inhibitor and OX40 receptor agonist. The Phase 1 trial is an open label, multi-center, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-279252 in patients with advanced solid tumors or lymphomas. SL-279252 is currently being developed in collaboration with Takeda Pharmaceuticals. Dose-escalation data from the trial are expected in the second half of 2021.
    • Presented Preclinical Data for SL-9258: Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a dual TIGIT inhibitor and HVEM/LTβR agonist, was presented at the American Association for Cancer Research (AACR) annual meeting in April 2021. These data demonstrated that SL-9258 (TIGIT-Fc-LIGHT) was highly active in a PD1 acquired resistance model and outperformed dual checkpoint blockade with anti-PD1 antibodies and anti-TIGIT antibodies.
    • Presented Continued Preclinical Development of GADLEN Platform: Preclinical proof of concept data on Shattuck's proprietary Gamma Delta T Cell Engager (GADLEN™) platform were presented at the AACR annual meeting in April 2021. These data demonstrated a multi-layer analysis to uncover the gamma and delta TCR usage in tumors and the butyrophilin expression pattern guiding the design of GADLEN therapeutics, which are intended to target both hematologic malignancies and solid tumor indications.

    First Quarter 2021 Financial Results

    • Cash Position: As of March 31, 2021, cash and cash equivalents and short-term investments were $321.2 million, as compared to $335.4 million as of December 31, 2020.
    • Research and Development (R&D) Expenses: R&D expenses for the first quarter ended March 31, 2021 were $10.3 million, as compared to $8.1 million for the first quarter ended March 31, 2020. The increase was primarily driven by an increase in our personnel related costs, expanded clinical development, and laboratory capabilities.
    • General and Administrative (G&A) Expenses: G&A expenses for the first quarter ended March 31, 2021 were $4.4 million, as compared to $1.6 million for the first quarter ended March 31, 2020. The increase was primarily driven by an increase in personnel related costs to support our activities associated with being a public company and operational expansion.
    • Net Loss: Net loss was $11.8 million for the first quarter ended March 31, 2021, or $0.28 per basic and diluted share, as compared to a net loss of $6.6 million for the first quarter ended March 31, 2020, or $0.86 per basic and diluted share.

    Expected 2021 Milestones

    Shattuck anticipates achieving the following milestones during 2021:

    SL-172154

    • Initial dose-escalation data from Phase 1 clinical trial in ovarian cancer expected in the second half of 2021
    • IND filings for SL-172154 in hematologic malignancies anticipated in the second half of 2021

    SL-279252

    • Dose-escalation data from Phase 1 clinical trial expected in the second half of 2021
    • Initiation of one or more dose-expansion cohorts expected in the second half of 2021

    Pipeline Advancements

    • Nomination of third ARC compound to clinical stage pipeline anticipated in the second half of 2021
    • Nomination of GADLEN lead compound anticipated in the second half of 2021

    2021 Financial Guidance

    Shattuck believes its cash and cash equivalents and short-term investments will be sufficient to fund its operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the Company's current operational plans and excludes any additional funding that may be received or business development or additional clinical development activities that may be undertaken.

    About SL-172154

    SL-172154 is an investigational bi-functional fusion protein designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway. SL-172154 is currently being evaluated in Phase 1 clinical trials for the treatment of patients with ovarian and head and neck or skin squamous cell carcinoma.

    In preclinical studies, SL-172154, demonstrated evidence of bridging the innate and adaptive immunity, antigen cross-priming to CD8+ T cells, and durable receptor occupancy, leading to superior anti-tumor activity over anti-CD47 antibodies, and anti-CD40 antibodies, both alone or in combination. Additionally, SL-172154 preclinically demonstrated a favorable safety profile with no evidence of hematologic toxicities observed with other CD47 inhibitors.

    About SL-279252

    SL-279252 is an investigational bi-functional fusion protein designed to block the PD-1 immune checkpoint and simultaneously agonize the OX40 pathway. SL-279252 is currently being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors and lymphoma. SL-279252 is part of a collaboration with Takeda Pharmaceuticals.

    In preclinical studies, SL-279252, demonstrated evidence of high monotherapy activity, potent stimulation of OX40+ T Cells and superior anti-tumor activity over anti-PD1/L-1 antibodies and anti-OX40 antibodies, both alone or in combination.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our preclinical studies, clinical trials and research and development programs, the initiation of any dose-expansion cohorts, the anticipated timing of the results from those studies and trials, the anticipated timing for IND filings, anticipated timing for preclinical development updates, the potential for our proprietary ARC technology and GADLEN platform, the clinical benefit of TIGIT blocking antibodies and T cell engagers, additional uses for our proprietary ARC technology and GADLEN platform, potential new uses for our product candidates, and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated shelter-in-place orders; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-Q for the quarter ended March 31, 2021, to be filed on May 10, 2021 with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com

     
    PART I - FINANCIAL INFORMATION
    Item 1. Financial Statements
    SHATTUCK LABS, INC.
    BALANCE SHEETS
    (In thousands)
     
     March 31,

    2021
    December 31,

    2020
     (unaudited) 
    Assets  
    Current assets:  
    Cash and cash equivalents$84,734 $157,898 
    Short-term investments236,442 177,551 
    Prepaid expenses and other current assets9,901 10,190 
    Total current assets331,077 345,639 
    Property and equipment, net5,411 3,000 
    Other assets362 349 
    Total assets$336,850 $348,988 
       
    Liabilities and Stockholders' Equity  
    Current liabilities:  
    Accounts payable$2,995 $1,754 
    Accrued expenses5,249 7,352 
    Deferred revenue9,659 7,728 
    Total current liabilities17,903 16,834 
    Deferred revenue, net of current portion18,088 21,306 
    Deferred rent2,197 987 
    Total liabilities38,188 39,127 
    Stockholders' equity:  
    Common stock5 5 
    Additional paid-in capital383,223 382,012 
    Accumulated other comprehensive loss(660)(63)
    Accumulated deficit(83,906)(72,093)
    Total stockholders' equity298,662 309,861 
    Total liabilities and stockholders' equity$336,850 $348,988 



     
    SHATTUCK LABS, INC.
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (Unaudited)
     
    (In thousands, except share and per share amounts)
     
     Three Months Ended March 31,
     2021 2020
    Collaboration revenue - related party$2,270  $2,976 
    Operating expenses:   
    Research and development10,337  8,137 
    General and administrative4,356  1,600 
    Expense from operations14,693  9,737 
    Loss from operations(12,423) (6,761)
        
    Other income (expense):   
    Interest income696  250 
    Other(86) (43)
    Total other income610  207 
    Net loss$(11,813) $(6,554)
    Unrealized gain (loss) on short-term investments(597) 61 
    Comprehensive loss$(12,410) $(6,493)
        
    Net loss per share – basic and diluted$(0.28) $(0.86)
    Weighted-average shares outstanding – basic and diluted41,774,111  7,620,838 


    Primary Logo

    View Full Article Hide Full Article
  7. AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, will participate in two upcoming conferences.

    Presentation Details
    Conference: 32nd Annual Cello Health Cancer Progress Conference
    Title: Multifunctional Soluble Biologics: Binders, Binders Everywhere
    Format: Panel discussion
    Date: May 5, 2021
    Time: 11:45 a.m. EST

    Conference: 17th Annual PEGS Boston Conference
    Title: Ranking Product Attributes to Select…

    AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, will participate in two upcoming conferences.

    Presentation Details

    Conference: 32nd Annual Cello Health Cancer Progress Conference

    Title: Multifunctional Soluble Biologics: Binders, Binders Everywhere

    Format: Panel discussion

    Date: May 5, 2021

    Time: 11:45 a.m. EST

    Conference: 17th Annual PEGS Boston Conference

    Title: Ranking Product Attributes to Select an Appropriate Expression Platform

    Format: Panel discussion

    Date: May 11, 2021

    Time: 12:20 p.m. EST

    The presentations and panel discussions will be available to registered conference attendees.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com 



    Primary Logo

    View Full Article Hide Full Article
  8. AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

    Presentation Details
    Conference: 7th Annual Truist Securities Life Sciences Summit
    Format: Fireside chat with analyst Asthika Goonewardene
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer
    Date: May 5, 2021
    Time: 1:50 p.m. EST…

    AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

    Presentation Details

    Conference: 7th Annual Truist Securities Life Sciences Summit

    Format: Fireside chat with analyst Asthika Goonewardene

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer

    Date: May 5, 2021

    Time: 1:50 p.m. EST

    Webcast Link: Available Here

    A live webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  9. AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

    TIGIT blocking antibodies have shown encouraging clinical activity in combination with PD-1/L1 blocking antibodies in checkpoint naïve NSCLC, if PD-L1 expression is high. Thus, opportunities to broaden the utility of combined PD-1/TIGIT blockade may be evident in either checkpoint…

    AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021.

    TIGIT blocking antibodies have shown encouraging clinical activity in combination with PD-1/L1 blocking antibodies in checkpoint naïve NSCLC, if PD-L1 expression is high. Thus, opportunities to broaden the utility of combined PD-1/TIGIT blockade may be evident in either checkpoint inhibitor (CPI) acquired resistant tumors, or tumors with low expression of PD-L1. Shattuck's presentation, titled "TNFSF14 (LIGHT) Co-Stimulation in Combination with Dual TIGIT/PD1 Checkpoint Inhibition (CPI) Induces Anti-Tumor Immunity in a CPI Acquired Resistance (AR) Model that Shares Transcriptional Similarities to Lung Cancer Patients Who Acquire Resistance to CPI," demonstrated that preclinically, SL-9258 (TIGIT-Fc-LIGHT) retained activity in a PD1 resistance model and outperformed dual checkpoint blockade with anti-PD1 and anti-TIGIT.

    The second poster highlighted expanded preclinical data from Shattuck's GADLEN™ platform. Titled "Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins," the poster demonstrated a multi-layer analysis to uncover the gamma and delta TCR usage in tumors and the butyrophilin expression pattern guiding the design of GADLEN therapeutics, which will target hematologic malignancies and solid tumor indications.

    "These two presentations are great examples of the potential for the ARC platform, and the ability of our internal R&D teams to rapidly innovate in response to emerging clinical data," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "First generation TIGIT blocking antibodies and T cell engagers are providing clinical benefit across a variety of tumor indications, and both SL-9258 and the GADLEN platform were created to address the remaining unmet medical need in CPI acquired resistant tumors, and solid tumor indications, respectively."

    The posters will be available under the Events & Presentations section of the Company's website.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, the potential for our proprietary ARC technology and GADLEN platform and the clinical benefit of TIGIT blocking antibodies and T cell engagers. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated shelter-in-place orders; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 16, 2021 with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  10. AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Needham's 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

    Presentation Details
    Conference: 20th Annual Needham Healthcare Conference
    Format: Fireside chat with covering analyst, Chad Messer, Ph.D.
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer
    Date: April 14, 2021
    Time: 11:00 a.m. EST
    Webcast Link…

    AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Needham's 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

    Presentation Details

    Conference: 20th Annual Needham Healthcare Conference

    Format: Fireside chat with covering analyst, Chad Messer, Ph.D.

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Chief Financial Officer

    Date: April 14, 2021

    Time: 11:00 a.m. EST

    Webcast Link: Available Here

    A live webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  11. AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the promotion of Andrew R. Neill to Chief Financial Officer from Vice President of Finance and Corporate Strategy.

    "Andrew is an incredibly experienced member of the Shattuck team and has made significant contributions to the company, including his key role in raising net proceeds of $330.5 million last year through our Series B and B-1 financings and initial public offering," said Taylor Schreiber, M.D., Ph.D., and Chief…

    AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the promotion of Andrew R. Neill to Chief Financial Officer from Vice President of Finance and Corporate Strategy.

    "Andrew is an incredibly experienced member of the Shattuck team and has made significant contributions to the company, including his key role in raising net proceeds of $330.5 million last year through our Series B and B-1 financings and initial public offering," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "Andrew's dedication and strategic impact will help Shattuck as we continue to advance our clinical-stage ARC compounds and GADLEN platform forward through clinical development."

    "As an early member of the Shattuck team, I am excited to continue building Shattuck and drive the company's growth from the CFO seat," said Mr. Neill. "I look forward to collaborating with all of our key stakeholders as we work to greatly improve treatment options for patients with cancer."

    Prior to joining Shattuck, Mr. Neill was the co-founder of Lumos Pharma, a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. He holds a Master's in Business Administration, with majors in Health Care Management and Finance, from The Wharton School at the University of Pennsylvania, where he was a Kaiser Fellow. Andrew holds a Bachelor of Business Administration from Texas Christian University.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  12. – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –

    – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 –

    AUSTIN, TX and DURHAM, NC, March 15, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided…

    – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –

    – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 –

    AUSTIN, TX and DURHAM, NC, March 15, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided recent business highlights.

    "2020 was a transformative year for Shattuck, and as we look ahead to 2021, we are excited to reveal the unique biology unlocked by the Agonist Redirected Checkpoint (ARC) technology in patients with cancer," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "We look forward to the Phase 1 data releases in the second half of this year for SL-172154 in patients with ovarian cancer and for SL-279252 in patients with advanced solid tumors. In addition, we are on-track to file an Investigational New Drug application in 2021 and to announce the lead candidate from our Gamma Delta T Cell Engager (GADLEN) platform. This is an exciting time for Shattuck and all of our stakeholders, and we believe that we are poised for years of clinical progress and expansion."

    Fourth Quarter 2020 Recent Business Highlights and Other Recent Developments

    • Continued Enrollment of Phase 1 Clinical Trial of SL-172154 in Ovarian Cancer: Shattuck continues to enroll patients in its Phase 1 clinical trial for its lead wholly owned asset SL-172154, a CD47/SIRPα inhibitor and CD40 agonist, and the second clinical program to advance from its proprietary ARC platform. The Phase 1 trial is an open label, multi-center dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 in patients with ovarian cancer. Initial Phase 1 dose-escalation data from the trial are expected in the second half of 2021.
    • Initiated Enrollment of Phase 1 Clinical Trial of SL-172154 in Head and Neck or Skin Squamous Cell Carcinoma: Shattuck also initiated a Phase 1 clinical trial for its lead wholly owned asset SL-172154, administered intratumorally. The Phase 1 trial will evaluate the safety, tolerability, and anti-tumor effects of SL-172154 in patients with squamous cell carcinoma of the head and neck or skin. Initial Phase 1 dose-escalation data from the trial are expected in the first half of 2022.
    • Continued Enrollment of Phase 1 Clinical Trial of SL-279252: Shattuck continues to enroll patients in its Phase 1 clinical trial evaluating SL-279252, a PD-1/PD-L1 inhibitor and OX40 receptor agonist. The Phase 1 trial is an open label, multi-center, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamics effects of SL-279252 in patients with advanced solid tumors or lymphomas. SL-279252 is currently being developed in collaboration with Takeda Pharmaceuticals. Phase 1 dose-escalation data from the trial are expected in the second half of 2021.
    • Presented Preclinical Development of SL-9258: Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a dual TIGIT inhibitor and HVEM/LTβR agonist, was released at the TIGIT Therapies Summit in October 2020. These data provided preclinical evidence for anti-tumor activity of the murine equivalent of SL-9258 in PD-1 resistant tumors and increased tumor rejection in comparison to TIGIT blocking antibodies.
    • Presented Preclinical Introduction of GADLEN Platform: Preclinical proof of concept data on Shattuck's proprietary GADLEN platform was presented at the Society for Immunotherapy of Cancer (SITC) Meeting in November 2020. GADLEN compounds were shown to stimulate proliferation and activation of gamma delta T cells in vivo and to target those expanded cells to a selected tumor antigen.
    • Completed Initial Public Offering (IPO): In October 2020, Shattuck completed an upsized IPO of common stock at $17.00 per share, raising gross proceeds of approximately $232.3 million and extending its cash runway through 2024.

    Upcoming Events

    • In April 2021, Shattuck will present an update on preclinical development of an in vivo model of checkpoint acquired resistance and updated information on its GADLEN platform at the American Association for Cancer Research (AACR) annual meeting.
    • Shattuck will attend the following investor conferences. Details of the presentations and webcasts will be announced prior to the events.

      ○  31st Annual Oppenheimer Healthcare Conference, March 16-18

      ○  20th Annual Needham Healthcare Conference, April 12-15

      ○  7th Annual Truist Securities Life Sciences Summit, May 4-5

    Fourth Quarter and Full Year 2020 Financial Results

    • Cash Position: As of December 31, 2020, cash and cash equivalents and short-term investments were $335.4 million, as compared to $39.1 million as of December 31, 2019. Net cash provided by financing activities for the year ended December 31, 2020 was $330.9 million, primarily comprised of approximately $117.0 million in net proceeds from Shattuck's Series B and B-1 financings and $213.5 million in net proceeds from Shattuck's IPO, completed in October 2020, partially offset by cash used in operating and investing activities.

    • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter ended December 31, 2020 were $9.8 million, as compared to $8.8 million for the fourth quarter ended December 31, 2019. R&D expenses for the year ended December 31, 2020 were $37.5 million, as compared to $29.2 million for the year ended December 31, 2019.
    • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter ended December 31, 2020 were $3.6 million, as compared to $1.7 million for the fourth quarter ended December 31, 2019. General and administrative expenses for the year ended December 31, 2020 were $9.4 million, as compared to $5.7 million for the year ended December 31, 2019.
    • Net Loss: Net loss was $12.0 million for the fourth quarter ended December 31, 2020, or $0.31 per basic and diluted share, as compared to a net loss of $7.4 million for the fourth quarter ended December 31, 2019, or $0.97 per basic and diluted share. Net loss for the year ended December 31, 2020 was $36.6 million, or $2.36 per basic and diluted share, as compared to $24.0 million, or $3.17 per basic and diluted share, for the year ended December 31, 2019. 

    2021 Financial Guidance

    Shattuck believes its cash and cash equivalents and short-term investments will be sufficient to fund its operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the Company's current operational plans and excludes any additional funding that may be received or business development or additional clinical development activities that may be undertaken.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our preclinical studies, clinical trials and research and development programs, the anticipated timing of the results from those studies and trials, anticipated timing for preclinical development updates, additional uses for our proprietary ARC technology and GADLEN platform, potential new uses for our product candidates, and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated shelter-in-place orders; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2020, to be filed on March 16, 2021 with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com

    Financials

     
    SHATTUCK LABS, INC.

    BALANCE SHEETS

    (In thousands)
      
     December 31,
     2020 2019
    Assets   
    Current assets:   
    Cash and cash equivalents$157,898  $7,013 
    Short-term investments177,551  32,074 
    Prepaid expenses and other current assets10,190  3,355 
    Total current assets345,639  42,442 
    Property and equipment, net3,000  2,437 
    Other assets349  90 
    Total assets$348,988  $44,969 
        
    Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)   
    Current liabilities:   
    Accounts payable$1,754  $3,051 
    Accrued expenses7,352  4,039 
    Deferred revenue — related party7,728  12,894 
    Total current liabilities16,834  19,984 
    Deferred revenue - related party net of current portion21,306  9,571 
    Deferred rent987  898 
    Total liabilities39,127  30,453 
        
        
    Series A redeemable convertible preferred stock  49,064 
    Series B redeemable convertible preferred stock   
    Series B-1 redeemable convertible preferred stock   
    Stockholders' equity (deficit):   
    Common stock5  1 
    Additional paid-in capital382,012  887 
    Accumulated other comprehensive income (loss)(63) 54 
    Accumulated deficit(72,093) (35,490)
    Total stockholders' equity (deficit)309,861  (34,548)
    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$348,988  $44,969 
            



     
    SHATTUCK LABS, INC.

    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In thousands, except share and per share amounts)
                    
     Three Months Ended

    December 31,

    (Unaudited)

     Twelve Months Ended

    December 31,

     2020

     2019

     2020 2019
    Collaboration revenue — related party$1,342  $2,821  $9,934  $9,887 
    Operating expenses:     
    Research and development 9,786   8,771  37,483  29,218 
    General and administrative 3,567   1,674  9,382  5,736 
    Expense from operations 13,353   10,445  46,865  34,954 
    Loss from operations (12,011)  (7,624) (36,931) (25,067)
          
    Other income (expense):     
    Interest income 75   282  549  1,184 
    Other (77)  (27) (221) (99)
    Total other income (2)  255  328  1,085 
    Net loss$(12,013) $(7,369) $(36,603) $(23,982)
    Other comprehensive income (loss):     
    Unrealized gain (loss) on investments (52)  (65) (117) 54 
    Comprehensive loss$(12,065) $(7,434) $(36,720) $(23,928)
          
    Net loss per share—basic and diluted$(0.31) $(0.97) $(2.36) $(3.17)
    Weighted-average shares outstanding—basic and diluted 38,800,057   7,595,332  15,506,067  7,556,812 
                  


    Primary Logo

    View Full Article Hide Full Article
  13. AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10-15, 2021. The first poster will highlight preclinical data from the company's GADLEN™ platform, while the second will highlight preclinical data from the development of an in vivo model of checkpoint acquired resistance and the therapeutic potential of SL-9258…

    AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10-15, 2021. The first poster will highlight preclinical data from the company's GADLEN™ platform, while the second will highlight preclinical data from the development of an in vivo model of checkpoint acquired resistance and the therapeutic potential of SL-9258 (TIGIT-Fc-LIGHT), derived from the company's ARC® platform, in an acquired resistance setting.

    Presentation Details

    Title: Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins

    Presenter: Dr. Suresh de Silva, Ph.D., Shattuck's Vice President of Product Development

    Virtual Session Date: April 10-15, 2021

    Virtual Session Location: E-Poster Session

    Abstract Number: 1736

    Title: The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities

    Presenter: Dr. George Fromm, Ph.D., Shattuck's Vice President of Research and Development

    Virtual Session Date: April 10-15, 2021

    Virtual Session Location: E-Poster Session

    Abstract Number: 1697

    Additional meeting information can be found on the AACR website, https://www.aacr.org. The posters will be available under the Events & Presentations section of the Company's website shortly after the event.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  14. AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

    Presentation Details
    Conference: Cowen 41st Annual Health Care Conference
    Format: Ovarian Cancer Panel discussion
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Date: March 2, 2021
    Time: 12:50 p.m. EST
    Webcast Link: The panel discussion will be available live to conference attendees

    Conference: Oppenheimer 31st Annual…

    AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

    Presentation Details

    Conference: Cowen 41st Annual Health Care Conference

    Format: Ovarian Cancer Panel discussion

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: March 2, 2021

    Time: 12:50 p.m. EST

    Webcast Link: The panel discussion will be available live to conference attendees

    Conference: Oppenheimer 31st Annual Healthcare Conference

    Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: March 16, 2021

    Time: 11:20 a.m. EST

    Webcast Link: Available Here

    The live webcast of the Oppenheimer presentation will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  15. AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi's 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

    Presentation Details
    Conference: Citi 2021 Virtual Immuno-Oncology Day
    Format: Group meeting with Andrew Baum and covering analyst Mohit Bansal
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy
    Date: February…

    AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi's 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

    Presentation Details

    Conference: Citi 2021 Virtual Immuno-Oncology Day

    Format: Group meeting with Andrew Baum and covering analyst Mohit Bansal

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: February 17, 2021

    Time: 12:00 p.m. EST

    Webcast Link: Available Here

    A live webcast will be available at the Events & Presentations section of the Company's website.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com 

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com 



    Primary Logo

    View Full Article Hide Full Article
  16. AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

    Presentation Details
    Conference: H.C. Wainwright BioConnect 2021 Conference
    Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy
    Date: January 11, 2021
    Time: 6:00 a.m. EST
    Webcast Link: Available Here

    The presentation will be available on-demand through the H.C. Wainwright conference portal…

    AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

    Presentation Details

    Conference: H.C. Wainwright BioConnect 2021 Conference

    Presenter: Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: January 11, 2021

    Time: 6:00 a.m. EST

    Webcast Link: Available Here

    The presentation will be available on-demand through the H.C. Wainwright conference portal and available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  17. AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.

    Presentation Details
    Conference: 39th Annual J.P. Morgan Healthcare Conference
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Date: January 14, 2021
    Time: 5:20 p.m. EST
    Webcast Link: Available Here

    The live webcast of the presentation will be available on the Events & Presentations section…

    AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.

    Presentation Details

    Conference: 39th Annual J.P. Morgan Healthcare Conference

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: January 14, 2021

    Time: 5:20 p.m. EST

    Webcast Link: Available Here

    The live webcast of the presentation will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 30 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  18. AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will be added to the Russell 2000® and 3000® Indexes effective December 21, 2020, following Russell's quarterly additions of select initial public offerings.

    "We are incredibly pleased to be included in the Russell 2000® and Russell 3000® Indexes," said Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy. "This milestone reflects the potential that investors see in Shattuck. Importantly, it…

    AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will be added to the Russell 2000® and 3000® Indexes effective December 21, 2020, following Russell's quarterly additions of select initial public offerings.

    "We are incredibly pleased to be included in the Russell 2000® and Russell 3000® Indexes," said Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy. "This milestone reflects the potential that investors see in Shattuck. Importantly, it increases our visibility in the investment community while broadening our institutional shareholder base."

    Russell indexes are part of FTSE Russell, a leading global index provider. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  19. AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

    Conference Presentation Details
    Conference: Evercore ISI 3rd Annual HealthCONx
    Format: Fireside chat with Umer Raffat
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy
    Date: December 2, 2020
    Time: 1:00 p.m. EST
    Webcast…

    AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

    Conference Presentation Details

    Conference: Evercore ISI 3rd Annual HealthCONx

    Format: Fireside chat with Umer Raffat

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

    Date: December 2, 2020

    Time: 1:00 p.m. EST

    Webcast Link: Available Here

    The live webcast of the fireside chat will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation dates.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Director of Finance

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
  20. – Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer –

    Completed initial public offering in October 2020 raising approximately $232.3 million in gross proceeds and extending cash runway through 2024 –

    AUSTIN, TX and DURHAM, NC, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

    "Shattuck has pioneered…

    – Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer –

    Completed initial public offering in October 2020 raising approximately $232.3 million in gross proceeds and extending cash runway through 2024 –

    AUSTIN, TX and DURHAM, NC, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

    "Shattuck has pioneered the development of bi-functional fusion proteins, and it is a testament to our team to be running multiple clinical trials in just four years from our founding," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "This has been a transformative year for Shattuck, and our additional clinical trials and support from a base of world-class investors was enabled by the clinical progress we have made to date. Shattuck now has the balance sheet and vast pipeline to support years of continued growth and execution, to aggressively develop SL-172154 as a differentiated asset in the CD47 field and to continue delivering on our partnership with Takeda Pharmaceuticals on SL-279252."

    Recent Business Highlights

    • Initiated Enrollment of Phase 1 Clinical Trial of SL-172154: In August 2020, Shattuck announced the initiation of a Phase 1 clinical trial for its lead wholly owned asset SL-172154, the second clinical program to advance from its proprietary Agonist Redirected Checkpoint (ARC) platform. SL-172154 is a bi-functional fusion protein that simultaneously blocks the CD47/SIRPα checkpoint and activates the tumor necrosis factor (TNF) costimulatory receptor CD40. The Phase 1 trial will initially evaluate the safety, tolerability, and anti-tumor effects of SL-172154 in patients with ovarian cancer. Initial Phase 1 dose escalation data from the trial are expected in the second half of 2021.



    • Continued Enrollment of Phase 1 Clinical Trial of SL-279252: The Company is continuing to enroll patients in its Phase 1 clinical trial evaluating SL-279252, a bi-functional fusion protein that simultaneously inhibits the PD-1/PD-L1 interaction and stimulates the OX40 receptor pathway in immune cells. The Phase 1 trial is an open label, multi-center, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity, and pharmacodynamics effects of SL-279252 in patients with advanced solid tumors or lymphomas. SL-279252 is currently being developed in collaboration with Takeda Pharmaceuticals. Phase 1 dose escalation data from the trial are expected in the second half of 2021.



    • Completed Initial Public Offering (IPO): In October 2020, Shattuck completed an upsized IPO of common stock at $17.00 per share, raising gross proceeds of approximately $232.3 million, before deducting underwriting discounts, commissions, and estimated offering costs.



    • Presented at TIGIT Therapies Summit: In October 2020, Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck, presented at the TIGIT Therapies Summit on exploring the novel method of modulating T cell function using TIGIT inhibition and presenting initial preclinical data of SL-9258 (TIGIT-Fc-LIGHT), a bi-functional fusion protein that simultaneously blocks the TIGIT/PVR checkpoint and activates the TNF costimulatory receptor known as LIGHT.



    • Advanced GADLEN Platform: The Company continues to advance its deep preclinical pipeline, including a second proprietary platform, the Gamma Delta T Cell Engager (GADLEN™) platform. In November 2020, Shattuck presented an update on the progress of the GADLEN platform at the Society for Immunotherapy of Cancer (SITC) Meeting.



    • Appointed New Director: In July 2020, Helen M. Boudreau was appointed to Shattuck's Board of Directors and currently serves as the Audit Committee chair and a member of the Compensation Committee. Ms. Boudreau brings over 30 years of corporate and financial expertise in the life sciences and healthcare industries.

    Third Quarter 2020 Financial Results

    • Cash and Investments: As of September 30, 2020, cash, cash equivalents, and short-term investments were $134.9 million, which does not include total net proceeds of approximately $213.5 million from the Company's IPO completed in October 2020.



    • Research and Development (R&D) Expenses: R&D expenses were $11.8 million for the third quarter of 2020, as compared to $7.9 million for the third quarter of 2019.



    • General and Administrative (G&A) Expenses: G&A expenses were $2.5 million for the third quarter of 2020, as compared to $1.4 million for the third quarter of 2019.



    • Net Loss: Net loss was $11.8 million for the third quarter of 2020, or $1.54 per basic and diluted share, as compared to a net loss of $7.3 million for the third quarter of 2019, or $0.96 per basic and diluted share.

    Financial Guidance

    The Company believes its cash, cash equivalents, and short-term investments, together with the net proceeds of its successful IPO on The Nasdaq Global Select Market will be sufficient to fund its anticipated operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the Company's current operational plans and excludes any additional funding that may be received or business development activities that may be undertaken.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our preclinical studies, clinical trials and research and development programs, the anticipated timing of the results from those studies and trials, and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated shelter-in-place orders; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, to be filed on November 13, 2020 with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Conor Richardson

    Director of Finance

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com

    Financials

    Shattuck Labs, Inc.    
    Condensed Balance Sheets    
    (Unaudited)    
    (In thousands, except share and per share amounts)    
          
       September 30, 2020 December 31, 2019
    Assets   
    Current assets:   
     Cash and cash equivalents$128,600  $7,013 
     Short-term investments 6,339   32,074 
     Prepaid expenses and other current assets 7,315   3,355 
      Total current assets 142,254   42,442 
    Property and equipment, net 2,515   2,437 
    Other assets 89   90 
      Total assets$ 144,858  $ 44,969 
          
    Liabilities, redeemable convertible preferred stock and stockholder' deficit   
    Current liabilities:   
     Accounts payable$1,350  $3,051 
     Accrued expenses 6,518   4,039 
     Deferred revenue – related party 8,613   12,894 
      Total current liabilities 16,481   19,984 
    Deferred revenue – related party net of current portion 19,722   9,571 
    Deferred rent 911   898 
      Total liabilities 37,114   30,453 
          
    Series A redeemable convertible preferred stock 49,064   49,064 
    Series B redeemable convertible preferred stock 34,427   - 
    Series B-1 redeemable convertible preferred stock 82,613   - 
          
    Stockholders' deficit:   
     Common stock 1   1 
     Additional paid-in capital 1,730   887 
     Accumulated other comprehensive income (loss) (10)  54 
     Accumulated deficit (60,081)  (35,490)
      Total stockholders' deficit (58,360)  (34,548)
      Total liabilities, redeemable convertible preferred stock and stockholders' deficit$ 144,858  $ 44,969 
          



    Shattuck Labs, Inc.     
    Condensed Statements of Operations     
    (Unaudited)     
    (In thousands, except share and per share amounts)     
              
       Three Months Ended September 30, Nine Months Ended September 30,
        2020   2019   2020   2019 
    Collaboration revenue – related party$2,435  $1,784  $8,592  $7,066 
    Operating expenses:       
     Research and development 11,804   7,945   27,696   20,447 
     General and administrative 2,470   1,366   5,816   4,062 
      Expense from operations 14,274   9,311   33,512   24,509 
    Loss from operations (11,839)  (7,527)  (24,920)  (17,443)
              
    Other income (expense):       
     Interest income 86   279   474   902 
     Other (76)  (31)  (145)  (72)
      Total other income 10   248   329   830 
    Net loss$(11,829) $(7,279) $(24,591) $(16,613)
    Unrealized gain (loss) on short-term investments (28)  10   (64)  119 
    Comprehensive loss$(11,857) $(7,269) $(24,655) $(16,494)
    Net loss per share – basic and diluted$(1.54) $(0.96) $(3.21) $(2.20)
    Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders—basic and diluted 7,700,371   7,572,746   7,656,077   7,543,831 
              

    Primary Logo

    View Full Article Hide Full Article
  21. AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of preclinical data from its Gamma Delta T Cell Engager, or GADLEN™, platform. The presentation, titled "In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells", will be presented by Suresh de Silva, Ph.D., VP of Product Development at Shattuck, at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which…

    AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of preclinical data from its Gamma Delta T Cell Engager, or GADLEN™, platform. The presentation, titled "In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells", will be presented by Suresh de Silva, Ph.D., VP of Product Development at Shattuck, at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020. The GADLEN platform is a novel class of bi-functional fusion proteins that are T cell engager molecules targeting gamma delta T cells to kill tumor cells expressing specific tumor antigens.

    The presentation demonstrates that a mouse butyrophilin heterodimer can activate mouse gamma delta T cells in vitro and in vivo to target the killing of lymphoma cells expressing the CD19 antigen. Additionally, the human heterodimeric fusion protein BTN2A1/3A1-Fc-CD19scFv, has also demonstrated its ability to bind both the V9V2 on gamma delta T cells and CD19 on lymphoma cells.

    "In vivo manipulation of gamma delta T cells holds great promise for treating cancers that are resistant or refractory to immune checkpoint blockade, however technical challenges have hindered this therapeutic goal until recently," said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. "These data indicate that dual-sided fusion proteins comprising butyrophilin heterodimers are well-suited to engage gamma delta T cells in vivo, stimulate those cells to proliferate and specifically kill CD19 positive tumor cells. While CD19 is a useful model antigen for feasibility, we believe these data pave the way to develop GADLEN compounds for a range of tumors and tumor antigens."

    The poster presentation will be available under the Events & Presentations section of the Company's website.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com

    Forward Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, our expectations regarding results from our preclinical studies and our expectations regarding our GADLEN platform, its promise for treating cancer and autoimmune diseases and its potential to address checkpoint refractory patients and other areas of high unmet needs. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "promises," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; and other risks and uncertainties identified in our Registration Statement on Form S-1 (File No. 333-248918), as amended, filed with the U.S. Securities and Exchange Commission. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Conor Richardson

    Director of Finance

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com

    Primary Logo

    View Full Article Hide Full Article
  22. AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, and other senior executives will participate in the Cowen 4th Annual IO Next Summit 2020 on November 13, 2020.

    Conference Presentation Details
    Conference: Cowen 4th Annual IO Next Summit
    Format: Fireside chat with covering analyst, Marc Frahm, Ph.D.
    Date: November 13, 2020
    Time: 2:15 p.m. EST
    Webcast Link: Available Here

    The live webcast of the fireside chat will…

    AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, and other senior executives will participate in the Cowen 4th Annual IO Next Summit 2020 on November 13, 2020.

    Conference Presentation Details

    Conference: Cowen 4th Annual IO Next Summit

    Format: Fireside chat with covering analyst, Marc Frahm, Ph.D.

    Date: November 13, 2020

    Time: 2:15 p.m. EST

    Webcast Link: Available Here

    The live webcast of the fireside chat will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Director of Finance

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com

    Primary Logo

    View Full Article Hide Full Article
  23. AUSTIN, TX and DURHAM, NC, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that preclinical data from its Gamma Delta T Cell Engager, GADLEN™, platform has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020.

    Presentation Details
    Title: In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells
    Date: November…

    AUSTIN, TX and DURHAM, NC, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that preclinical data from its Gamma Delta T Cell Engager, GADLEN™, platform has been accepted for poster presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020.

    Presentation Details

    Title: In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells

    Date: November 11 – 14, 2020

    Time: 9:00 a.m. – 5:00 p.m. EST

    Location: Virtual Poster Hall

    Abstract Number: 688

    Additional meeting information can be found on the SITC website at www.sitcancer.org. The poster presentation will be available under the Events & Presentations section of the Company's website.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com

    Investor Contact:

    Conor Richardson

    Director of Finance

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com

    Primary Logo

    View Full Article Hide Full Article
  24. DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the CD47|SIRPα Summit 2020 being held virtually November 4-5, 2020.

    Presentation Details
    Presentation Title: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity
    Presentation Subtitle: Preclinical and Clinical Development of SL-172154
    Date/Time: November 5 at 10:45 a.m. EST
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive…

    DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the CD47|SIRPα Summit 2020 being held virtually November 4-5, 2020.

    Presentation Details

    Presentation Title: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity

    Presentation Subtitle: Preclinical and Clinical Development of SL-172154

    Date/Time: November 5 at 10:45 a.m. EST

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Location: https://www.cd47sirpa.com/

    The presentation will be available for download on the Events & Presentations section of the Company's website and also will be available to registered participants of CD47|SIRPα Summit 2020.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint platform, ARC®, simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Director of Finance

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com

    Primary Logo

    View Full Article Hide Full Article
  25. Shattuck Labs, Inc. ("Shattuck"), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the TIGIT Therapies Digital Summit 2020 being held virtually October 26 – 27, 2020.

    Presentation Details
    Presentation Title: Using LIGHT to Hotwire TIGIT Blockade
    Date/Time: October 26at 10:00 a.m. EDT
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Location: www.tigit-therapies.com

    The presentation will be available for download on the Events & Presentations section of the Company's website and also will be available to registered participants…

    Shattuck Labs, Inc. ("Shattuck"), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the TIGIT Therapies Digital Summit 2020 being held virtually October 26 – 27, 2020.

    Presentation Details

    Presentation Title: Using LIGHT to Hotwire TIGIT Blockade

    Date/Time: October 26 at 10:00 a.m. EDT

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Location: www.tigit-therapies.com

    The presentation will be available for download on the Events & Presentations section of the Company's website and also will be available to registered participants of TIGIT Therapies Digital Summit 2020.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint platform, ARC®, simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: www.ShattuckLabs.com.

    View Full Article Hide Full Article
  26. Shattuck Labs, Inc. ("Shattuck"), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the closing of its upsized initial public offering of 13,664,704 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,782,352 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Shattuck from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, were approximately $232.3 million. All of the shares in the offering were offered…

    Shattuck Labs, Inc. ("Shattuck"), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the closing of its upsized initial public offering of 13,664,704 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,782,352 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Shattuck from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, were approximately $232.3 million. All of the shares in the offering were offered by Shattuck. The shares began trading on The Nasdaq Global Select Market on October 9, 2020 under the ticker symbol "STTK."

    Citigroup, Cowen, and Evercore ISI acted as joint book-running managers for the offering. Needham & Company acted as lead manager for the offering.

    The registration statements relating to these securities became effective on October 8, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at (800) 831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, by telephone at (833) 297-2926; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck's ARC platform

    simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas.

    View Full Article Hide Full Article